+1 (310) 663-7831

PRODUCTS

NeOnc Technologies is aggressively pursuing research and development of a wide range of  POH-based delivery products to improve the safety and efficacy of pharma-therapeutics for the treatment of CNS diseases. In addition, the company is also developing a line of topically applied skin therapeutics that can offer effective treatment of skin issues.

NEO 100

Internasal Perillyl Alcohol Formulation for the treatment of Grade IV Gliomas.

NEO 100 is a highly purified form of the natural compound Perillyl Alcohol (POH). POH is a natural substance isolated from the essential oils of lavender, peppermint, spearmint, cherries, celery seeds, and several other plants. Research evidence has shown that POH can interfere with the replication of dividing cells such as seen in cancer. POH has shown antitumor activity against a range of cancer types including pancreatic, lung, colon, and liver cancers in laboratory and animal studies and an inhaled form of POH has shown preliminary evidence of safety and effectiveness in patients with recurrent gliomas.

NEO100 serves as the base component of each of NeOnc Technologies product line. 

NEO 100 is currently undergoing clinical testing in the United States in Phase I and II trials. It is delivered intranasal and is the validation trial for the Fonseca Phase II trial being performed in Brazil. It has IND in the U.S. for the treatment of recurrent malignant gliomas. Trials are being conducted at five active sites: University of Southern California (USC), Cleveland Clinic, University of Washington, University of Wisconsin, and Cleveland Clinic in Florida. The purpose of the trails are to validate that daily inhalation of NEO100 is safe for the patients and does not cause severe side effects and to evaluate the therapeutic impact of NEO100 on the patient’s cancer.

NEO 100 has already received Orphan drug and Fast Track status with the FDA.

NEO 100 is being tested as an internasal delivery molecule for the treatment of Grade IV gliomas. Grade IV gliomas are among the most aggressive and deadly forms of brain cancers, and patients with this form of cancer face a grim prognosis. Only a quarter of newly diagnosed Glioblastoma patients survive for 24 months, and fewer than 10 percent of patients survive more than 5 years.

Globally, approximately 300,000 men and women are diagnosed with cancer of the brain and nervous system every year, and more than 240,000 deaths are caused by the disease. It is also one of the primary cancers that affect children and young adults.

 

NEO 102

An isoform of our highly purified Perillyl Alcohol formulation engineered to promote anti-cancer activity especially in lung cancer. 

NEO 102 is an isoform of our highly purified Perillyl Alcohol formulation. Our preliminary studies indicate promising anti-cancer activity of this compound, in particular against lung cancer cells.

Patents granted in the US, Europe, and Japan.

No trials are being conducted at this time.

NEO 104

A variant of our highly purified Perillyl Alcohol formulation to provide longer-lasting therapeutic effects.

NEO 104 is a variant of our highly purified Perillyl Alcohol formulation. It has been engineered to replace one of the compound’s hydrogen atoms with its deuterium isotope. This variant is being studied to determine if it can provide a lower rate of metabolism for a wrapped combinatorial agent in order to provide longer-lasting therapeutic effects.

A provisional patent has been filed internationally.

No trials are being conducted at this time.

NEO 212

Conjugation of Temozolomide and Perillyl Alcohol for the treatment of Malignant Gliomas.

NEO 212 is a chemical conjugation of the DNA alkylating agent Temozolomide (TMZ) with our highly purified formulation of Perillyl Alcohol (POH). TMZ continues to be the gold standard in the treatment of anaplastic astrocytoma, and glioblastoma multiforme cancersIt works by slowing or stopping the growth of cancer cells in your body. Recent studies have shown the 1-year and 2-year survival rates were 37.8% and 10.4% with radiation plus temozolomide, versus 22.2% and 2.8% with radiation therapy alone. 

The NEO 212 formulation was designed to see if increased efficacy TMZ could be achieved through internasal delivery within the patented wrapper technology.

NeOnc Technologies is continuing ongoing studies to determine the benefit of the TMZ/POH conjugate. Early pre-clinical research shows that NEO 212 is ten times more potent, five times less toxic than TMZ, five times more stable, and three times more effective blood-brain barrier penetrance compared to TMZ on its own.

NEO 212 has been tested in acute and chronic (small and large animal) testing at Charles Rivers in Montreal, Canada in an oral formulation, with the dose-limiting toxicity of myelotoxicity. It has also been examined in non-GLP testing for intranasal delivery at Charles Rivers in Willmington, Maryland. Orphan drug status for malignant gliomas has been granted and by year-end it is hoped that application for Investigational New Drug (IND) status will be completed.

The primary target for Temozolomide (TMZ) is glioblastoma multiforme. It is estimated that close to 25, 000 people in the United States will be diagnosed with primary cancerous tumors of the brain and spinal cord this year. Brain tumors account for 85% to 90% of all primary central nervous system (CNS) tumors. Since treatment using TMZ is generally through a series of oral dosages or by intravenous infusion, its effectiveness is inhibited by the need for uptake to occur through the intestinal or circulatory system. Primary side-effects include bone marrow suppression, nausea, vomiting, constipation, loss of appetite, and more. 

NEO 212 hopes to improve efficacy while minimizing the side-effect issues currently associated with TMZ treatment.

NEO 214

Conjugation of Rolipram and Perillyl Alcohol for the treatment of autoimmune diseases, Alzheimer’s, and other CNS and respiratory issues.

NEO 214  is a chemical conjugation of the phosphodiesterase type IV inhibitor Rolipram with our highly purified formulation of Perillyl Alcohol (POH). Though initially developed as an antidepressant drug in the early 1990s, Rolipram has several corollary effects that make it a promising candidate in the treatment of many neurodegenerative diseases. In the case of Alzheimer’s, Rolipram studies have shown a marked ability to enhance the ability of proteasome to break up the accumulation of misfolded and clumped proteins that accumulate in the brain which are associated with the disease, as well as with other memory and cognitive disorders. 

NeOnc Technologies continues its research into the ability of its NEO 214 formulation to enhance the ability of Rolipram to be used in the treatment of cognitive disorders. To date, the company has been able to show that Rolipram delivered via the NEO 214 wrapper is 1,000 times more potent than oral Rolipram alone.

Rolipram is classified as a  phosphodiesterase type 4 inhibitor (PDE4) because of its ability to block the action of phosphodiesterase type 4 enzymes from breaking the messenger bonds between cAMP molecules which are critical to regulating the biological activity of proteins. As such PDE4 is seen as a potential strong agent in being able to treat neuro-cognitive issues such as Alzheimer’s, to provide improved long term memory, increased wakefulness, increased neuroprotection, and to assist in faster recovery for axonal regeneration and spinal cord lesions.

Additionally, PDE4 has been shown to reduce the effects of respiratory inflammation in issues such as asthma and COPD.

NEO 216

Conjugation of Valproic Acid and Perillyl Alcohol for the treatment of seizure and bipolar disorders.

NEO 216 is a proprietary conjugate formulation of Valproic Acid with our highly purified form of Perillyl Alcohol (POH). It has been created to provide an internasal delivery mechanism for VPA. Valproate (VPA), in its Valproic Acid form, is used to treat epilepsy, bipolar disorder, migraine headaches, and is useful in the prevention of seizures in those with absence seizures, partial seizures, and generalized seizures. Currently, it is administered via tablet forms in both long- and short-acting formulations as well as intravenous delivery. By providing intranasal delivery Neonc Technologies hopes to show better efficacy and lower side-effect results can be obtained.

No trials are currently being conducted at this time.

Though the exact mechanisms of VPA are still being studied, it is believed that it works by affecting GABA levels in the brain thereby blocking voltage-gated sodium channels, and inhibiting histone deacetylases which are associated with seizures. Studies have shown that VPA is helpful in decreasing seizures associated with Epilepsy and brain trauma as well as being an anti-manic depressant for those with bipolar disease. VPA has also proven effective in decreasing the pain and effects of migraine headaches and has even shown some preliminary positive therapeutic results in treating Schizophrenia.

NEO 218

Conjugation of 3-Bromopyruvate and Perillyl Alcohol for inhibiting the metabolic growth of cancer cells. 

NEO 218 is a conjugate formulation of 3-Bromopyruvate (3BP) and our highly refined Perillyl Alcohol (POH). 3BP is a small, highly reactive molecule noted for its high efficacy for anticancer therapy, especially for its antitumor properties. 3BP works by inhibiting energy production pathways of cancer cells without harming normal cells. 3BP also has the capacity to induce multiple forms of cancer cell death and is being studied for its antimicrobial activity. 3BP however has several issues related to drug toxicity int its current delivery methodology. An example is a noted burning venous sensation In intravenous delivery. By creating an internasal delivery wrapper for 3BP it is hoped these toxicity issues can be ameliorated.  

A provisional IP has been filed. 

A research paper is pending publication.

3-Bromopyruvate (3BP) is being studied as a general anti-cancer therapeutic. The drug has the ability to inhibit the energy production of cancer cells thus slowing or preventing growth. The compound works by addressing the “Warburg Effect” of cancer cells that shows how cancer cell reproduction has an abnormal dependence on metabolizing glucose even when sufficient oxygen is present, which is how normal cells proliferate. By blocking the ability of cancer cells to uptake glucose, cell growth is reduced. 

Delivery of the drug though is one of the key factors in limiting efficacy due to side-effects of its toxicity to other systems and its need to travel systemically through the body to get to a tumor site where potency can be degraded. NEO 218 promises to bring a much higher efficacy to 3BP therapy by providing immediate, full potency delivery of the therapeutic to patients suffering from brain cancer. 

NEO 312

Conjugate of Dopamine and Perillyl Alcohol for the treatment of Parkinson’s disease. 

NEO 312 is the conjugation of Dopamine and our highly purified Perillyl Alcohol(POH). Dopamine is a naturally occurring neurotransmitter that is most associated with the pleasure/reward mechanism of the brain. It has also been associated with Parkinson’s disease where the loss of dopamine-secreting neurons in an area of the midbrain called the substantia nigra is directly correlated to the tremor and motor impairment associated with Parkinson’s. 

Currently, oral medications such as Levodopa and Carbidopa are used to increase dopamine levels in the brain as part of a Parkinson’s treatment program. However, the side effects and potency degradation associated with the systemic delivery lessen the impact of the therapeutic. In providing a direct internasal delivery methodology to the brain, NeOnc Technologies is hoping to dramatically increase the benefits and efficacy of this treatment. 

No trials are being conducted at this time.

It is estimated that about one million Americans are thought to have Parkinson’s. This is more than those affected by multiple sclerosis, muscular dystrophy, and amyotrophic lateral sclerosis (ALS) combined. The combined direct and indirect costs of Parkinson’s in the U.S. including treatment, disability, and similar costs, plus lost income from an inability to work, are estimated at $25 billion per year. The average cost of Parkinson’s medication is $2,500 per year. Parkinson’s-related surgery can cost up to $100,000 per patient. Dopamine-based therapy still remains one of the most common drug therapies used to combat Parkinson’s.

NEO 312 promises to offer an a cost-effective and targeted solution to Dopamine delivery to treat this disease in order to provide better outcomes from those suffering from Parkinson’s.

NEO 400

Conjugation of Linoleic Acid and Perillyl Alcohol to protect and restore skin from UV damage. Also to help diminish skin wrinkling.

NEO 400 is a conjugate formulation of Linolic Acid (LA) and our highly purified form of Perillyl Alcohol (POH). NEO 400 was created as a topical compound to assist with protecting skin from UV damage pre-exposure and as a restorative for post-exposure UV damage. NEO 400 takes advantage of the uptake and anti-inflammatory activities of LA and the anti-proliferative and anti-invasive properties of our POH formulation to deliver a very effective anti-skin cancer protectant. NEO 400 is also being studied for its effectiveness as an anti-wrinkle therapy because of its ability to restore suppleness to the skin.

NeOnc Technologies is currently conducting a human study on the effects of its NEO 400 topical skin therapy in decreasing wrinkles and dry skin. As Linoleic Acid (LA) is an Omega-6 essential fatty acid, it has proven to be able to provide moisture and “plumpness” to surface epidermis without weighing down the skin. Combined with our POH base, preliminary data suggests NEO 400 can increase the effectiveness of LA in increasing in epidermal thickness, improved cell turnover, and increased cell differentiation in the stratum corneumIt also shows an impact on lightening sun-induced hyperpigmentation. 

If the trial data is successful, a determination will be made whether NEO 400 could be added to the consumer OTC products that limit exposure to UV rays but provide no specific protection for cancer prevention.

As a topical skin treatment NEO400 shows great promise in providing both preventative and restorative benefits for skin damage caused by intense UV exposure. NeOnc Technologies is fast-tracking its research and approval certification paperwork in order to begin the regulatory approval process. As a topical cream, NEO 400 can be approved through the less restrictive and time-consuming cosmetic approval process and it can be sold as a non-controlled OTC product. As such NEO400 could be revenue-producing in as little as 12-18 months.

NEO 412

A triple conjugate of Temozolomide, Linolic Acid and Perillya Alcohol formulated to help treat skin melanomas and basal cell carcinomas.

NEO 412 was created to build on the therapeutic effect of its NEO 400 formulation. Whereas NEO 400 provides a non-disease specific benefit to skin damage caused by UV exposure, NEO 412 is targeting the treatment of melanoma and basal skin cancers by adding Temozolomide (TMZ) to the formulation. TMZ is a gold standard therapeutic for cancer treatment that works by slowing or stopping the growth of cancer cells. By adding this to our NEO 412 product in a topical application, the product will provide a targeted benefit to decreasing subcutaneous melanoma tumor size and spread in a patient. 

NeOnc Technologies has conducted research that showed that NEO 412 tested in a subcutaneous melanoma model on mice demonstrated a successful decrease in tumor size using a cutaneous (topical) application. Additional testing showed that NEO 412 also shows promise in actinic keratosis and skin melanomas in human volunteers.

Further testing is being conducted to show efficacy in treating melanomas, basal cell carcinoma, cutaneous T-cell lymphomas, and neurinomas.

NEO 412 is targeted as a therapeutic for those suffering a variety of early-stage skin cancers where local topical treatment may prove efficacious as opposed to surgical procedure which is more costly and has more potential side effects.

NeOnc Technologies hopes to provide a viable treatment option for the more than 9,500 people who are diagnosed with skin cancer each and every day in the U.S. It is estimated that 196,060 cases of melanoma will be diagnosed in the U.S. in 2020. Of those, 95,710 cases will be in situ (noninvasive) melanomas where NEO 412 may offer effective relief.

PRODUCTS

NeOnc c Technologies is aggressively pursuing research and development of a wide range of  POH-based delivery products to improve the safety and efficacy of pharma-therapeutics for the treatment of CNS diseases. In addition, the company is also developing a line of topically applied skin therapeutics that can offer effective treatment of skin issues.

NEO 100

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

NEO 100 is a highly purified form of the natural compound Perillyl Alcohol (POH). POH is a natural substance isolated from the essential oils of lavender, peppermint, spearmint, cherries, celery seeds, and several other plants. Research evidence has shown that POH can interfere with the replication of dividing cells such as seen in cancer. POH has shown antitumor activity against a range of cancer types including pancreatic, lung, colon, and liver cancers in laboratory and animal studies and an inhaled form of POH has shown preliminary evidence of safety and effectiveness in patients with recurrent gliomas.

NEO100 serves as the base component of each of NeOnc Technologies product line. 

NEO 100 is currently undergoing clinical testing in the United States in Phase I and II trials. It is delivered intranasal and is the validation trial for the Fonseca Phase II trial being performed in Brazil. It has IND in the U.S. for the treatment of recurrent malignant gliomas. Trials are being conducted at five active sites: University of Southern California (USC), Cleveland Clinic, University of Washington, University of Wisconsin, and Cleveland Clinic in Florida. The purpose of the trails are to validate that daily inhalation of NEO100 is safe for the patients and does not cause severe side effects and to evaluate the therapeutic impact of NEO100 on the patient’s cancer.

NEO 100 has already received Orphan drug and Fast Track status with the FDA.

NEO 100 is being tested as an internasal delivery molecule for the treatment of Grade IV gliomas. Grade IV gliomas are among the most aggressive and deadly forms of brain cancers, and patients with this form of cancer face a grim prognosis. Only a quarter of newly diagnosed Glioblastoma patients survive for 24 months, and fewer than 10 percent of patients survive more than 5 years.

Globally, approximately 300,000 men and women are diagnosed with cancer of the brain and nervous system every year, and more than 240,000 deaths are caused by the disease. It is also one of the primary cancers that affect children and young adults.

 

NEO 102

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

NEO 102 is an isoform of our highly purified Perillyl Alcohol formulation. Our preliminary studies indicate promising anti-cancer activity of this compound, in particular against lung cancer cells.

Patents granted in the US, Europe, and Japan.

No trials are being conducted at this time.

NEO 104

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

NEO 104 is a variant of our highly purified Perillyl Alcohol formulation. It has been engineered to replace one of the compound’s hydrogen atoms with its deuterium isotope. This variant is being studied to determine if it can provide a lower rate of metabolism for a wrapped combinatorial agent in order to provide longer-lasting therapeutic effects.

A provisional patent has been filed internationally.

No trials are being conducted at this time.

NEO 212

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

NEO 212 is a chemical conjugation of the DNA alkylating agent Temozolomide (TMZ) with our highly purified formulation of Perillyl Alcohol (POH). TMZ continues to be the gold standard in the treatment of anaplastic astrocytoma, and glioblastoma multiforme cancersIt works by slowing or stopping the growth of cancer cells in your body. Recent studies have shown the 1-year and 2-year survival rates were 37.8% and 10.4% with radiation plus temozolomide, versus 22.2% and 2.8% with radiation therapy alone. 

The NEO 212 formulation was designed to see if increased efficacy TMZ could be achieved through internasal delivery within the patented wrapper technology.

NeOnc Technologies is continuing ongoing studies to determine the benefit of the TMZ/POH conjugate. Early pre-clinical research shows that NEO 212 is ten times more potent, five times less toxic than TMZ, five times more stable, and three times more effective blood-brain barrier penetrance compared to TMZ on its own.

NEO 212 has been tested in acute and chronic (small and large animal) testing at Charles Rivers in Montreal, Canada in an oral formulation, with the dose-limiting toxicity of myelotoxicity. It has also been examined in non-GLP testing for intranasal delivery at Charles Rivers in Willmington, Maryland. Orphan drug status for malignant gliomas has been granted and by year-end it is hoped that application for Investigational New Drug (IND) status will be completed.

The primary target for Temozolomide (TMZ) is glioblastoma multiforme. It is estimated that close to 25, 000 people in the United States will be diagnosed with primary cancerous tumors of the brain and spinal cord this year. Brain tumors account for 85% to 90% of all primary central nervous system (CNS) tumors. Since treatment using TMZ is generally through a series of oral dosages or by intravenous infusion, its effectiveness is inhibited by the need for uptake to occur through the intestinal or circulatory system. Primary side-effects include bone marrow suppression, nausea, vomiting, constipation, loss of appetite, and more.

NEO 212 hopes to improve efficacy while minimizing the side-effect issues currently associated with TMZ treatment.

NEO 214

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

NEO 214  is a chemical conjugation of the phosphodiesterase type IV inhibitor Rolipram with our highly purified formulation of Perillyl Alcohol (POH). Though initially developed as an antidepressant drug in the early 1990s, Rolipram has several corollary effects that make it a promising candidate in the treatment of many neurodegenerative diseases. In the case of Alzheimer’s, Rolipram studies have shown a marked ability to enhance the ability of proteasome to break up the accumulation of misfolded and clumped proteins that accumulate in the brain which are associated with the disease, as well as with other memory and cognitive disorders.

NeOnc Technologies continues its research into the ability of its NEO 214 formulation to enhance the ability of Rolipram to be used in the treatment of cognitive disorders. To date, the company has been able to show that Rolipram delivered via the NEO 214 wrapper is 1,000 times more potent than oral Rolipram alone.

Rolipram is classified as a  phosphodiesterase type 4 inhibitor (PDE4) because of its ability to block the action of phosphodiesterase type 4 enzymes from breaking the messenger bonds between cAMP molecules which are critical to regulating the biological activity of proteins. As such PDE4 is seen as a potential strong agent in being able to treat neuro-cognitive issues such as Alzheimer’s, to provide improved long term memory, increased wakefulness, increased neuroprotection, and to assist in faster recovery for axonal regeneration and spinal cord lesions.

Additionally, PDE4 has been shown to reduce the effects of respiratory inflammation in issues such as asthma and COPD.

NEO 216

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

NEO 216 is a proprietary conjugate formulation of Valproic Acid with our highly purified form of Perillyl Alcohol (POH). It has been created to provide an internasal delivery mechanism for VPA. Valproate (VPA), in its Valproic Acid form, is used to treat epilepsy, bipolar disorder, migraine headaches, and is useful in the prevention of seizures in those with absence seizures, partial seizures, and generalized seizures. Currently, it is administered via tablet forms in both long- and short-acting formulations as well as intravenous delivery. By providing intranasal delivery Neonc Technologies hopes to show better efficacy and lower side-effect results can be obtained.

No trials are currently being conducted at this time.

Though the exact mechanisms of VPA are still being studied, it is believed that it works by affecting GABA levels in the brain thereby blocking voltage-gated sodium channels, and inhibiting histone deacetylases which are associated with seizures. Studies have shown that VPA is helpful in decreasing seizures associated with Epilepsy and brain trauma as well as being an anti-manic depressant for those with bipolar disease. VPA has also proven effective in decreasing the pain and effects of migraine headaches and has even shown some preliminary positive therapeutic results in treating Schizophrenia.

NEO 218

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

NEO 218 is a conjugate formulation of 3-Bromopyruvate (3BP) and our highly refined Perillyl Alcohol (POH). 3BP is a small, highly reactive molecule noted for its high efficacy for anticancer therapy, especially for its antitumor properties. 3BP works by inhibiting energy production pathways of cancer cells without harming normal cells. 3BP also has the capacity to induce multiple forms of cancer cell death and is being studied for its antimicrobial activity. 3BP however has several issues related to drug toxicity int its current delivery methodology. An example is a noted burning venous sensation In intravenous delivery. By creating an internasal delivery wrapper for 3BP it is hoped these toxicity issues can be ameliorated.  

A provisional IP has been filed. 

A research paper is pending publication.

3-Bromopyruvate (3BP) is being studied as a general anti-cancer therapeutic. The drug has the ability to inhibit the energy production of cancer cells thus slowing or preventing growth. The compound works by addressing the “Warburg Effect” of cancer cells that shows how cancer cell reproduction has an abnormal dependence on metabolizing glucose even when sufficient oxygen is present, which is how normal cells proliferate. By blocking the ability of cancer cells to uptake glucose, cell growth is reduced. 

Delivery of the drug though is one of the key factors in limiting efficacy due to side-effects of its toxicity to other systems and its need to travel systemically through the body to get to a tumor site where potency can be degraded. NEO 218 promises to bring a much higher efficacy to 3BP therapy by providing immediate, full potency delivery of the therapeutic to patients suffering from brain cancer. 

NEO 312

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

NEO 312 is the conjugation of Dopamine and our highly purified Perillyl Alcohol(POH). Dopamine is a naturally occurring neurotransmitter that is most associated with the pleasure/reward mechanism of the brain. It has also been associated with Parkinson’s disease where the loss of dopamine-secreting neurons in an area of the midbrain called the substantia nigra is directly correlated to the tremor and motor impairment associated with Parkinson’s. 

Currently, oral medications such as Levodopa and Carbidopa are used to increase dopamine levels in the brain as part of a Parkinson’s treatment program. However, the side effects and potency degradation associated with the systemic delivery lessen the impact of the therapeutic. In providing a direct internasal delivery methodology to the brain, NeOnc Technologies is hoping to dramatically increase the benefits and efficacy of this treatment. 

No trials are being conducted at this time.

It is estimated that about one million Americans are thought to have Parkinson’s. This is more than those affected by multiple sclerosis, muscular dystrophy, and amyotrophic lateral sclerosis (ALS) combined. The combined direct and indirect costs of Parkinson’s in the U.S. including treatment, disability, and similar costs, plus lost income from an inability to work, are estimated at $25 billion per year. The average cost of Parkinson’s medication is $2,500 per year. Parkinson’s-related surgery can cost up to $100,000 per patient. Dopamine-based therapy still remains one of the most common drug therapies used to combat Parkinson’s.

NEO 312 promises to offer an a cost-effective and targeted solution to Dopamine delivery to treat this disease in order to provide better outcomes from those suffering from Parkinson’s.

NEO 400

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

NEO 400 is a conjugate formulation of Linolic Acid (LA) and our highly purified form of Perillyl Alcohol (POH). NEO 400 was created as a topical compound to assist with protecting skin from UV damage pre-exposure and as a restorative for post-exposure UV damage. NEO 400 takes advantage of the uptake and anti-inflammatory activities of LA and the anti-proliferative and anti-invasive properties of our POH formulation to deliver a very effective anti-skin cancer protectant. NEO 400 is also being studied for its effectiveness as an anti-wrinkle therapy because of its ability to restore suppleness to the skin.

NeOnc Technologies is currently conducting a human study on the effects of its NEO 400 topical skin therapy in decreasing wrinkles and dry skin. As Linoleic Acid (LA) is an Omega-6 essential fatty acid, it has proven to be able to provide moisture and “plumpness” to surface epidermis without weighing down the skin. Combined with our POH base, preliminary data suggests NEO 400 can increase the effectiveness of LA in increasing in epidermal thickness, improved cell turnover, and increased cell differentiation in the stratum corneumIt also shows an impact on lightening sun-induced hyperpigmentation. 

If the trial data is successful, a determination will be made whether NEO 400 could be added to the consumer OTC products that limit exposure to UV rays but provide no specific protection for cancer prevention.

As a topical skin treatment NEO400 shows great promise in providing both preventative and restorative benefits for skin damage caused by intense UV exposure. Neonc Technologies is fast-tracking its research and approval certification paperwork in order to begin the regulatory approval process. As a topical cream, NEO 400 can be approved through the less restrictive and time-consuming cosmetic approval process and it can be sold as a non-controlled OTC product. As such NEO 400 could be revenue-producing in as little as 12-18 months.

NEO 412

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

NEO 412 was created to build on the therapeutic effect of its NEO 400 formulation. Whereas NEO 400 provides a non-disease specific benefit to skin damage caused by UV exposure, NEO 412 is targeting the treatment of melanoma and basal skin cancers by adding Temozolomide (TMZ) to the formulation. TMZ is a gold standard therapy for cancer treatment that works by slowing or stopping the growth of cancer cells. By adding this to our NEO 412 product in a topical application, the product will provide a targeted benefit to decreasing subcutaneous melanoma tumor size and spread in a patient. 

Neonc Technologies has conducted research that showed that NEO 412 tested in a subcutaneous melanoma model on mice demonstrated a successful decrease in tumor size using a cutaneous (topical) application. Additional testing showed that NEO 412 also shows promise in actinic keratosis and skin melanomas in human volunteers.

Further testing is being conducted to show efficacy in treating melanomas, basal cell carcinoma, cutaneous T-cell lymphomas, and neurinomas.

NEO 412 is targeted as a therapeutic for those suffering a variety of early-stage skin cancers where local topical treatment may prove efficacious as opposed to surgical procedure which is more costly and has more potential side effects.

NeOnc Technologies hopes to provide a viable treatment option for the more than 9,500 people who are diagnosed with skin cancer each and every day in the U.S. It is estimated that 196,060 cases of melanoma will be diagnosed in the U.S. in 2020. Of those, 95,710 cases will be in situ (noninvasive) melanomas where NEO 412 may offer effective relief.